Pantoprazole

Pantoprazole is a widely utilized medication in the proton pump inhibitor (PPI) class, designed to reduce gastric acid production. It was originally discovered and developed by the German pharmaceutical firm Byk Gulden, which later became part of Altana Pharma. The molecule was patented in 1985 and was eventually brought to the global market following clinical success in treating gastroesophageal reflux disease (GERD) and peptic ulcers.

In 2007, the Danish pharmaceutical giant Nycomed acquired Altana's pharmaceutical division, thereby becoming the steward of the Pantoprazole brand (often marketed under the name Protonix early on). However, Nycomed was subsequently acquired by Takeda Pharmaceutical Company in 2011. Today, Takeda remains the primary innovator and owner of the original brand, though the production of the medication has become highly decentralized. Because the patent has expired, pantoprazole is manufactured by numerous generic pharmaceutical companies worldwide, including giants like Teva, Sandoz, and Mylan, in facilities ranging from India and China to Europe and North America.